Madrigal Pharmaceuticals, Inc. (MDGL)
Nasdaq · Healthcare · Biotechnology
$493.62−1.16%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.4B
- Forward P/E
- 51.3
- 52-week range
- $393.61 – $615.00
- 52-week change
- +12.91%
- EPS (trailing)
- −$12.85
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $958M (+432.06%)
- Net income
- −$288M
- Operating margin
- −31.3%
- Diluted EPS
- −$10.15
- Free cash flow
- −$190M
From the company’s annual report on SEC EDGAR.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Headquarters: West Conshohocken, United States · 915 employees · madrigalpharma.com